European Union - English - EMA (European Medicines Agency)

genzyme europe b.v. - alemtuzumab - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents - mabcampath is indicated for the treatment of patients with b-cell chronic lymphocytic leukaemia (bcll) for whom fludarabine combination chemotherapy is not appropriate.

Israel - English - Ministry of Health

sanofi israel ltd - alemtuzumab - concentrate for solution for infusion - alemtuzumab 12 mg / 1.2 ml - alemtuzumab - lemtrada is indicated as a single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: • patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) or • patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.